|
A novel HDAC inhibitor in late stage clinical development for Peripheral T-cell Lymphoma, and other Solid Tumors (including Carcinoma of Unknown Primary, etc.)
More Info about Belinostat
| Drug Type: | Cancer |
| Current FDA Status: | Unknown |
| Current Drug Phase: | Phase 2 |
|